SAVA vs. LQDA, PLRX, INVA, ABVX, ORIC, ARQT, EOLS, WVE, TYRA, and SPRY
Should you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include Liquidia (LQDA), Pliant Therapeutics (PLRX), Innoviva (INVA), ABIVAX Société Anonyme (ABVX), ORIC Pharmaceuticals (ORIC), Arcutis Biotherapeutics (ARQT), Evolus (EOLS), Wave Life Sciences (WVE), Tyra Biosciences (TYRA), and ARS Pharmaceuticals (SPRY). These companies are all part of the "medical" sector.
Liquidia (NASDAQ:LQDA) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.
Liquidia has higher revenue and earnings than Cassava Sciences. Liquidia is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.
Liquidia received 87 more outperform votes than Cassava Sciences when rated by MarketBeat users. However, 66.20% of users gave Cassava Sciences an outperform vote while only 66.06% of users gave Liquidia an outperform vote.
Cassava Sciences has a net margin of 0.00% compared to Cassava Sciences' net margin of -448.89%. Liquidia's return on equity of -57.53% beat Cassava Sciences' return on equity.
Liquidia has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -0.42, suggesting that its share price is 142% less volatile than the S&P 500.
45.0% of Liquidia shares are held by institutional investors. Comparatively, 27.2% of Cassava Sciences shares are held by institutional investors. 31.6% of Liquidia shares are held by company insiders. Comparatively, 10.1% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Liquidia had 6 more articles in the media than Cassava Sciences. MarketBeat recorded 18 mentions for Liquidia and 12 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.45 beat Liquidia's score of 0.25 indicating that Liquidia is being referred to more favorably in the media.
Liquidia presently has a consensus target price of $21.00, indicating a potential upside of 34.96%. Cassava Sciences has a consensus target price of $124.00, indicating a potential upside of 482.71%. Given Liquidia's stronger consensus rating and higher possible upside, analysts plainly believe Cassava Sciences is more favorable than Liquidia.
Summary
Liquidia beats Cassava Sciences on 10 of the 17 factors compared between the two stocks.
Get Cassava Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SAVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Cassava Sciences Competitors List
Related Companies and Tools